Investigating the therapeutic effects and deciphering the underlying mechanisms of IL-22 could lead to the development of novel therapies for DN, thus providing scientific basis for therapeutic strategies for DKD on the basis of simultaneous regulation of metabolism and NLRP3 inflammasome activation. This evidence concerns the gene NLRP3 and liver dysplastic nodule.